Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Hemoglobin01:24

Hemoglobin

Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026
Same author

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same author

Contrast-Associated AKI in Hospitalized Adults With Sickle Cell Disease.

Kidney international reports·2026
Same author

Perioperative management of adult sickle cell disease patients requiring cardiac surgery: A 25-year experience in a referral center.

Anaesthesia, critical care & pain medicine·2026
Same author

A Rare Case of Homozygous HbE With Coinherited Alpha-Thalassemia and Hb Constant Spring in a Neonate Reveals a Mild Hematologic Phenotype.

Journal of pediatric hematology/oncology·2026
Same author

Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.

HemaSphere·2026

相关实验视频

Updated: Jun 19, 2026

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

26.3K

在Voxelotor治疗期间胎儿血红蛋白降低

Gonzalo De Luna1, Anoosha Habibi1, Stéphane Moutereau2

  • 1Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, Créteil, France.

European journal of haematology
|October 21, 2024
PubMed
概括

在状细胞病患者的Voxelotor治疗导致6个月后胎儿血红蛋白 (HbF) 水平下降. 这一发现引发了人们对Voxelotor因其短半衰期而停止使用后潜在的反弹效应的担忧.

关键词:
这是一个Voxelotor.这是胎儿血红蛋白.血液形成 血液形成状细胞疾病是一种状细胞疾病.

更多相关视频

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Published on: May 5, 2018

11.5K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

2.8K

相关实验视频

Last Updated: Jun 19, 2026

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

26.3K
Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Published on: May 5, 2018

11.5K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

2.8K

科学领域:

  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.
  • 遗传学 遗传学 是一个

背景情况:

  • 沃克塞洛托改善了状细胞疾病 (SCD),通过修改血红蛋白与氧的亲和力,减少贫血和血液溶解.
  • 在SCD患者中,Voxelotor对胎儿血红蛋白 (HbF) 水平的影响仍然基本不明.
  • 了解HbF动态对于管理SCD及其并发症至关重要.

研究的目的:

  • 研究Voxelotor治疗对状细胞患者胎儿血红蛋白 (HbF) 水平的影响.
  • 在6个月的治疗期间分析HbF百分比和平均体质HbF的变化.
  • 探索SCD管理和治疗终止的潜在影响.

主要方法:

  • 在接受Voxelotor治疗的SCD患者中,对HbF水平的回顾性分析.
  • 使用高性能液态染色学 (HPLC) 测量HbF百分比.
  • 在接受治疗的患者中评估体质平均HbF (mchF).

主要成果:

  • 在Voxelotor治疗6个月后,在状细胞患者中观察到HbF水平的显著下降.
  • 这种HbF的减少可能与红细胞寿命的延长有关,特别是那些HbF较低的红细胞.
  • 该研究观察到队列中HbF百分比和mchF的变化.

结论:

  • 在状细胞患者中,Voxelotor治疗与胎儿血红蛋白水平的降低有关.
  • 观察到的HbF下降可能是红细胞存活率增加的间接影响.
  • 需要进行进一步的研究,以解决Voxelotor中断后HbF水平反弹的风险,考虑到其短半衰期.